Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: Relationship with pregnancy outcome and thrombosis

American Journal of Reproductive Immunology

Volumn 62, Issue 6, 2009, Pages 381-389

  Martinez Zamora, Maria Angeles ^a   Tassies, Dolors ^b   Carmona, Francisco ^a   Espinosa, Gerard ^d   Cervera, Ricard ^d   Reverter, Juan Carlos ^b   Balasch, Juan ^a  

^a Inst Clin Gynecol   (Spain)

^b

^c Spain

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiphospholipid syndrome; Clot lysis time; Pregnancy; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE; CYSTEINE; DNA; GLYCINE; LOW MOLECULAR WEIGHT HEPARIN; THREONINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT SELECTION; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLEEDING TIME; CARBOXYPEPTIDASE U; FEMALE; GENE FREQUENCY; HUMANS; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; THROMBOSIS;

EID: 70450197757     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2009.00751.x     Document Type: Article

References (48)

1. Levine JS, Rauch J, Branch DW. Anti-phospholipid syndrome. N Engl J Med 2002, 346:752-763.
2. Carmona F, Font J, Azulay M, Creus M, Fabregues F, Cervera R, Puerto B, Balasch J. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001, 46:274-279.
3. Branch DW, Silver R, Blackwell J, Reading J, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992, 80:614-620.
4. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmunity Rev 2003, 2:86-93.
5. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008, 34:236-250.
6. Forastiero R, Martinuzzo M. Prothombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008, 17:872-877.
7. Carmona F, Lazaro I, Reverter JC, Tassies D, Font J, Cervera R, Balasch J. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. Am J Obstet Gynecol 2006, 194:457-465.
8. Yasuda S, Atsumi T, Ieko M, Koike T. Beta2-glycoprotein I, anti-beta2-glicoprotein I, and fibrinolysis. Thromb Res 2004, 114:461-465.
9. Curnow JL, Morel-Kopp MC, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost 2007, 5:528-534.
10. Gombas J, Tanka-Salamon A, Skopal J, Nagy Z, Machovich R, Kolev K. Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins. Blood Coagul Fibrinolysis 2008, 19:82-88.
11. Bouma BN, Meijers JC. Thombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypectidase U). J Thromb Haemost 2003, 1:1566-1574.
12. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998, 273:27176-27181.
13. Mosnier LO, Meijers JCM, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001, 85:5-11.
14. Zhao L, Morser J, Bajzar L, Neisheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998, 80:949-955.
15. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli V, Maffei FH, Ferrari IC, Piccinato CEWA, Zago MA. Identification of polymorphisms in the 5′-untranslated region of the tafi gene: relationship with plasma TAFI levels and risk of venous thombosis. Haematologica 2001, 86:510-517.
16. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Jhan-Vague I. Identification of polymorphisms in the promoter and the 3′region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001, 97:2053-2058.
17. Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneider M, Boffa M, Koschinsky M, Van Tilburg NH, Nesheim ME, Bertina RM, Garcia EBG. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001, 98:1992-1993.
18. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Goumelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000, 20:2156-2161.
19. He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma I. Method design and preliminary results. Thromb Res 1999, 96:145.
20. Curnow JL, Morel-Kopp M-C, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost 2006, 5:528-534.
21. He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of hemostasis potential en plasma II. Modifications for use in laboratories and research work. Thromb Res 2001, 103:335-361.
22. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Aydin HH, Tombuloglu M, Doganavsargil E. Thrombin activatable fibrinolysis inhibitor in Behçet′s disease. Thromb Res 2005, 115:287-292.
23. Ricart JM, Ramon LA, Vaya A, España F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A. Fibrinolytic inhibitor levels and the polymorphisms in Behçet disease and their association with trombosis. Br J Haematol 2008, 141:716-719.
24. Ringwald J, Buettner S, Zimmermann R, Weisbach V, Strasser E, Eckstein R, Eckel K, Manger K. Thrombin-activatable fibrinolysis inhibitor and activated factor XII in patients with systemic lupus erythematosus. Thromb Res 2007, 119:129-131.
25. Patterson AM, Ford I, Graham A, Booth NA, Greaves M. The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells. Br J Haematol 2006, 133:323-330.
26. Chetaille P, Alessi MC, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000, 83:902-905.
27. Chabloz P, Reber G, Boehlen F, Hohlfeld P, DeMoerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001, 115:150-152.
28. Mousa HA, Downey C, Alfirevic Z, Toh C. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost 2004, 92:1025-1031.
29. Watanabe T, Minakami H, Sakata Y, Matsubara S, Sato I, Suzuki M. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy. Gynecol Obstet Invest 2004, 58:19-21.
30. Wright JG, Cooper P, Astedt B, Lecander I, Wilde JT, Preston FE, Greaves M. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988, 69:253-258.
31. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res 2005, 116:345-356.
32. Antovic JP, Rafik Hamad R, Antovic A, Blomback M, Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb Haemost 2002, 88:644-647.
33. Alacacioglu I, Ozcan MA, Alacacioglu A, Polat M, Yuksel F, Demirkan F, Piskin O, Ozgenc Y, Ozsan HG, Undar B. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Research 2004, 114:155-159.
34. Sucak GT, Acar K, Sucak A, Kirazli S, Haznedar R. Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia. Blood Coagul Fibrinol 2006, 17:347-352.
35. De Maat MPM, Jansen MWJC, Hille ETM, Vos HL, Bloemerkamp KWM, Buitendkijk S, Helmerhorst FM, Wladimiroff JW, Bertina RM, De Groot CJM. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004, 2:1588-1593.
36. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
37. Balasch J, Carmona F, Creus M, Font J, Cervera R, Asherson RA, Cervera R, Piette R-C, Schoenfeld Y. Management of reproductive failure in the antiphospholipid syndrome. The Antiphospholipid Syndrome II: Autoimmune Thrombosis 2002, 375-394. eds, Amsterdam, Elsevier Science B.V, pp
38. ACOG practice bulletin Perinatal care at the threshold of viability. No. 38, September 2002. Int J Gynaecol Obstet 2002, 79:181-188.
39. Nimrod CA, Gruslin A, Reece A, Hobbind JC. Biology of normal and deviant fetal growth. Medicine of the Fetus and the Mother 1999, 267-278. 2nd edn, eds, Philadelphia, Lippincott-Raven Publishers, pp
40. Witlin AG, Sibai B, Reece A, Hobbind JC. Hypertensive diseases in pregnancy. Medicine of the Fetus and the Mother 1999, 997-1020. 2nd edn, eds, Philadelphia, Lippincott-Raven Publishers, pp
41. Bamberg C, Kalache KD. Prenatal diagnosis of fetal growth restriction. Semin Fetal Neonatal Med 2004, 9:387-394.
42. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria the diagnosis of lupus anticoagulant: an update Subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995, 74:1185-1190.
43. Gils A, Alessi MC, Browers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotipe 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003, 23:1122-1127.
44. Lisman T, Leebek FWG, Meijer K, Van Der Meer J, Nieuwenhuis K, DeGroot P. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002, 35:616-621.
45. D′Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. AJRI 2007, 58:150-158.
46. Lisman T, deGroot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk for venous thrombosis. Blood 2005, 105:1102-1105.
47. Cellai AP, Antonucci E, Liotta AA, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 2006, 118:494-500.
48. Schroeder V, Kucher N, Kohler HP. Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism. J Thromb Haemost 2003, 1:492-493.